Back to previous section

Accrol FY earnings in line despite weaker-than-expected sales growth

Tissue convertor Accrol said on Tuesday that adjusted earnings were projected to be in line with expectations, despite a lower than anticipated increase in sales resulting from consumer Covid-19 panic-buying in the early stages of the pandemic.

  • Accrol Group Holdings
  • 16 April 2024 13:55:19

Source: Sharecast

Accrol noted that sales across the whole industry had been depressed in recent months, while consumer stockpiling unwound, with total revenues increasing 1.5% to £136.8m in the trading year ended 30 April and volumes declining 3.9% on a like-for-like basis, against a total market decline of 5.5%.

The AIM-listed group did note that its market share had increased from 13% to 16% and pointed out that it had also continued to increase its share with discount retailers, despite a sector decline of 12% in the year.

Net debt was cut from £18.1m to £14.6m on a pre-IFRS16 basis.

Chief executive Gareth Jenkins said: "In this pandemic year, we have fully automated our largest factory, installed a business-wide operating system, and grown our margins further. We now have a business capable of benefitting further, as the UK exits lockdown, and we remain excited about the future for the group."

As of 1310 BST, Accrol shares had slumped 12.90% to 54.0p.

FTSE AIM All-Share ( AXX )

Isin: N/A
Exchange: London Stock Exchange
Sell:
0.00
Buy:
0.00
Change: -9.64 ( -1.28 %)
Date:
Prices delayed by at least 15 minutes

Compare our accounts

Whether you're looking for a Share Dealing Account or Share Dealing ISA, we've got an account to suit your needs.

View our accounts

Lloyds Bank is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

The Lloyds Bank Direct Investments Service is operated by Halifax Share Dealing Limited. Registered Office: Trinity Road, Halifax, West Yorkshire, HX1 2RG. Registered in England and Wales no. 3195646. Halifax Share Dealing Limited is authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under registration number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

Logo Allfunds

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

FE fundinfo Logo

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

Refinitiv Logo

© 2024 Refinitiv, an LSEG business. All rights reserved.